BACKGROUND: Understanding the long-term effect of alemtuzumab on the immune system of multiple sclerosis (MS) patients is crucial. OBJECTIVE: To report a case of acute sarcoidosis (Löfgren's syndrome) in a relapsing-remitting MS patient, 1.5 years after the second course of alemtuzumab treatment. CASE REPORT: Sarcoidosis was confirmed dermatohistologically, radiologically, and serologically. Analysis of the lymphocyte subpopulations showed a persistent effect of alemtuzumab treatment (CD4/CD8 ratio increased, absolute lymphocyte count of CD19-positive cells increased while CD3/4/8-positive cells were decreased). CONCLUSION: Our case highlights the profound effect of alemtuzumab on the immune system and its possible risk for autoimmune complications.
BACKGROUND: Understanding the long-term effect of alemtuzumab on the immune system of multiple sclerosis (MS) patients is crucial. OBJECTIVE: To report a case of acute sarcoidosis (Löfgren's syndrome) in a relapsing-remitting MSpatient, 1.5 years after the second course of alemtuzumab treatment. CASE REPORT: Sarcoidosis was confirmed dermatohistologically, radiologically, and serologically. Analysis of the lymphocyte subpopulations showed a persistent effect of alemtuzumab treatment (CD4/CD8 ratio increased, absolute lymphocyte count of CD19-positive cells increased while CD3/4/8-positive cells were decreased). CONCLUSION: Our case highlights the profound effect of alemtuzumab on the immune system and its possible risk for autoimmune complications.
Authors: Tobias Ruck; Sumanta Barman; Andreas Schulte-Mecklenbeck; Steffen Pfeuffer; Falk Steffen; Christopher Nelke; Christina B Schroeter; Alice Willison; Michael Heming; Thomas Müntefering; Nico Melzer; Julia Krämer; Maren Lindner; Marianne Riepenhausen; Catharina C Gross; Luisa Klotz; Stefan Bittner; Paolo A Muraro; Tilman Schneider-Hohendorf; Nicholas Schwab; Gerd Meyer Zu Hörste; Norbert Goebels; Sven G Meuth; Heinz Wiendl Journal: Brain Date: 2022-06-03 Impact factor: 15.255